At its much-anticipated analysts' meeting in early April, Pfizer Inc. was vague in explaining exactly how exactly the pharmaceutical giant would both trim an unexpectedly bulky $4 billion from its costs by 2008 (twice the figure expected by most analysts) and return the company to double-digit adjusted earnings growth as early as 2006 (2005, CFO David Shedlarz predicted, would see a modest profit decline). Quite a few observers suggest this can't be done without significant layoffs from sales force and R&D cuts that Pfizer says it won't resort to.
Now the company must pull off this Houdiniesque escape wearing the equivalent of a blindfold handed to it by the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?